Guangzhou Weimi Bio-Tech Co.
Latest round
- Series A
Last raised
- Nov 2018
Total raised
- Undisclosed
Investors
- 2
About Guangzhou Weimi Bio-Tech Co.
, Ltd. is a biotechnology company that focuses on the research, development, and sales of vitro diagnostic technology and point-of-care testing products. Its products and diagnostic services include detection of the pathogenic microorganism, inflammation, cardiovascular disease, and prenatal testing.
Who invested in Guangzhou Weimi Bio-Tech Co.
2 investors across 1 round
See all investors in Guangzhou Weimi Bio-Tech Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 27, 2018
Amount
Undisclosed
Investors
Questions about Guangzhou Weimi Bio-Tech Co.
Who invested in Guangzhou Weimi Bio-Tech Co.?
Guangzhou Weimi Bio-Tech Co. has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Guangzhou Weimi Bio-Tech Co. raised?
Guangzhou Weimi Bio-Tech Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Guangzhou Weimi Bio-Tech Co. last raise money?
Guangzhou Weimi Bio-Tech Co.'s most recent round on record is a Series A, in Nov 2018.
What does Guangzhou Weimi Bio-Tech Co. do?
Guangzhou Weimi Bio-Tech Co. is a biotechnology company.
Where is Guangzhou Weimi Bio-Tech Co. headquartered?
Guangzhou Weimi Bio-Tech Co. is headquartered in Guangzhou, China.
Which VCs invest in companies like Guangzhou Weimi Bio-Tech Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Guangzhou Weimi Bio-Tech Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Guangzhou Weimi Bio-Tech Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.